IP Library › Granted Patent US 12,371,669
Granted Patent B2
US 12,371,669 · App. 17/980,820 · Granted Jul 29, 2025

Kidney organoids and method for producing the same

Inventors: Dong Sung Kim (Pohang-si, KR); Tae Eun Park (Ulsan, KR); Hyeon Ji Lim (Ulsan, KR); Do Hui Kim (Incheon, KR)
Assignees: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION; UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
C12N5/0697C12N2500/02C12N2501/119C12N2501/16C12N2506/45C12N2513/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,669
App. No.
17/980,820
Granted
Jul 29, 2025
Kind
B2
Abstract

Disclosed is a method for producing kidney organoids including steps of: (1) differentiating stem cells into metanephric mesenchyme cells; (2) forming metanephric mesenchyme cell aggregates by culturing the metanephric mesenchyme cells; and (3) differentiating the metanephric mesenchyme cell aggregates into kidney organoids.

Claims (13)

1. A method for producing human kidney organoids comprising:

(A) differentiating human pluripotent stem cells into metanephric mesenchyme cells by:

(i) culturing the human pluripotent stem cells in a first medium containing a GSK-3β inhibitor and a BMP4 inhibitor on Day 0,

(ii) culturing the human pluripotent stem cells in a second medium containing Activin A on day 4,

(iii) culturing the human pluripotent stem cells in a third medium containing 10 ng/ml of FGF9 on day 7;

(B) forming metanephric mesenchyme cell aggregates by culturing the metanephric mesenchyme cells in a fourth medium containing a GSK-3p inhibitor and 10 ng/ml of FGF9 on Day 9; and

(C) differentiating the metanephric mesenchyme cell aggregates into kidney organoids in a fifth medium containing FBS on day 14 for 7 to 100 days and culturing the metanephric mesenchyme cells in a sixth medium containing 25 ng/ml to 50 ng/ml of FGF9 on Day 11 to form kidney organoids;

wherein steps (B) and (C) are performed in a porous microwell formed of a permeable porous membrane comprising at least one concave portion,

wherein the at least one concave portion is formed at the bottom and an opening is formed at the top of the microwell,

wherein the porous microwells facilitate supply of nutrients and growth factors and removal of metabolites.

2. The method according to claim 1 , wherein step (A) of differentiating the human pluripotent stem cells into the metanephric mesenchyme cells is performed in a hypoxic environment with an oxygen concentration lower than 10%.

3. The method according to claim 1 , wherein step (A) of differentiating the pluripotent stem cells into the metanephric mesenchyme cells is performed for 8 days to 9 days.

4. The method according to claim 1 , wherein step (B) of forming the metanephric mesenchyme cell aggregates is performed for 2 days to 3 days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2022
From: KIM, DONG SUNG; PARK, TAE EUN; LIM, HYEON JI; KIM, DO HUI
To: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION; UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
Reel/Frame 061657/0506 →
Priority Claims (2)
KR 10-2021-0153107 · Nov 9, 2021 · national
KR 10-2022-0120733 · Sep 23, 2022 · national
Continuity (1)
Related Publication 20230142476A1 · May 11, 2023
References Cited (22)
US 10369254B2 · Yanagawa et al. · 2019 [cited by applicant]
US 20180258404A1 · Bonventre · 2018 [cited by examiner]
US 20200248147A1 · Homan · 2020 [cited by examiner]
US 20220073852A1 · Lee · 2022 [cited by examiner]
JP 2015123028 · 2015 [cited by applicant]
JP 2017537655 · 2017 [cited by applicant]
JP 2018102285 · 2018 [cited by applicant]
JP 2018527007 · 2018 [cited by applicant]
KR 20200010279 · 2020 [cited by applicant]
KR 1020200081853 · 2020 [cited by applicant]
WO 2016094948 · 2016 [cited by applicant]
WO WO2016094948A1 · 2016 [cited by examiner]
WO 2020019023 · 2020 [cited by applicant]
WO WO2020138581A1 · 2020 [cited by examiner]
Futrega et al. The microwell-mesh: A novel device and protocol for the high throughput manufacturing of cartilage microtissues (2015) Biomaterials, 62, pp. 1-12. (Year: 2015). [cited by examiner]
Gupta et al. Microfluidics-based 3D cell culture models: Utility in novel drug discovery and delivery research (2016) Bioengineering & Translational Medicine, 1, pp. 63-81. (Year: 2016). [cited by examiner]
Minoru Takasato et al., “Generation of kidney organoids from human pluripotent stem cells”, Nature Protocols vol. 11, pp. 1681-1692 , Aug. 18, 2016. [cited by applicant]
EPO, Search Report of EP 22205804.2 dated Feb. 23, 2023. [cited by applicant]
Kohei Uchimura et al., “Human Pluripotent Stem Cell-Derived Kidney Organoids with Improved Collecting Duct Maturation and Injury Modeling”, Cell Reports 33, 108514, Dec. 15, 2020, https://doi.org/10.1016/j.celrep.2020.1… [cited by applicant]
KIPO, Office Action of KR 10-2021-0153107 dated Jun. 21, 2024. [cited by applicant]
Ramírez-Bergeron, Diana L., et al. “Hypoxia affects mesoderm and enhances hemangioblast specification during early development.” Development 131 (Sep. 2004): 4623-4634. doi: 10.1242/dev.01310. [cited by applicant]
JPO, Office Action of the corresponding Japanese Patent Application No. 2022-178961 dated Nov. 28, 2023. [cited by applicant]